{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":18,"total_is_capped":false,"direct_labels_cover":0,"predictions_cover":18,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"f45526ca5810","filters":{"venue":"ESMO rare cancers."}},"results":[{"id":"W4417530834","doi":"10.1016/j.esmorc.2025.100073","title":"RADIOLOGIC RESPONSES IN EPITHELIOID HEMANGIOENDOTHELIOMA: BEYOND RECIST?","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Dermatological and Skeletal Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research","funders":"Memorial Sloan-Kettering Cancer Center","keywords":"Feature (linguistics); Medical imaging; Disease; MEDLINE; Computed tomography","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.006966873779264059,"gpt":0.2581287047792288,"spread":0.2511618309999647,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001382667,0.0001656393,0.0002173207,0.0001180626,0.00006251337,0.00001602485,0.0002541155,0.0001738486,0.00007702679],"category_scores_gemma":[0.0002329529,0.000139509,0.0001173441,0.0002987871,0.0001530305,0.000003899866,0.00009703327,0.0001143212,0.00002199651],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004900755,"about_ca_system_score_gemma":0.0001350939,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005622737,"about_ca_topic_score_gemma":0.0001623589,"domain_scores_codex":[0.9988723,0.0001175308,0.0002218835,0.0004198222,0.00007212389,0.0002963802],"domain_scores_gemma":[0.9995129,0.00003823535,0.0000444472,0.0003243006,0.00003294718,0.00004714612],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.004850769,0.0005044984,0.1546615,0.0003522518,0.0004924002,0.0007583181,0.000349157,0.000552326,0.3961233,0.01167236,0.2788701,0.1508131],"study_design_scores_gemma":[0.003315808,0.0004249791,0.05884376,0.0001074003,0.00003080648,0.00007205298,0.000348178,0.0000558546,0.1430511,0.01739351,0.7755738,0.0007827544],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9436401,0.01309677,0.0002781062,0.001969217,0.0003735991,0.000251634,0.00003945324,0.00003532588,0.04031581],"genre_scores_gemma":[0.9876196,0.00099423,0.0001749849,0.002703319,0.00004792607,0.00007611491,0.0000570152,0.00001030199,0.008316501],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4967037,"threshold_uncertainty_score":0.5689013,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417530891","doi":"10.1016/j.esmorc.2025.100116","title":"THE TETRAVALENT DEATH RECEPTOR 5 AGONIST OZEKIBART (INBRX-109) IN CHONDROSARCOMA: RESULTS FROM THE RANDOMIZED, REGISTRATIONAL, PHASE 2 CHONDRAGON STUDY","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Bone Tumor Diagnosis and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research","funders":"University of Colorado School of Medicine, Anschutz Medical Campus; European Network for Rare Adult Solid Cancers; Feinberg School of Medicine; Centre Léon Bérard; Universitair Medisch Centrum Groningen; Cleveland Clinic; University College London; Institut Gustave-Roussy; Vanderbilt University; Moffitt Cancer Center; Universiteit Leiden; Leids Universitair Medisch Centrum; University of California, San Francisco; Vanderbilt University Medical Center; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; Johns Hopkins University; University of Texas MD Anderson Cancer Center; Northwestern University; Vanderbilt-Ingram Cancer Center; Memorial Sloan-Kettering Cancer Center","keywords":"Agonist; Placebo; Clinical trial; Receptor; Phase (matter)","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.02316641315826398,"gpt":0.3242507285497494,"spread":0.3010843153914854,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007886402,0.0003233887,0.0006861024,0.00007148948,0.0005014314,0.0001334358,0.0003130656,0.00008480885,0.0001213443],"category_scores_gemma":[0.0007944678,0.0001785212,0.0002373013,0.0003964176,0.0002695631,0.00008871702,0.00006494302,0.000436961,0.0000353569],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007119823,"about_ca_system_score_gemma":0.0006799317,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.007758896,"about_ca_topic_score_gemma":0.004095236,"domain_scores_codex":[0.9973602,0.0003691124,0.0007992305,0.0006178423,0.0004745678,0.0003790463],"domain_scores_gemma":[0.9968838,0.001738618,0.0002288177,0.0009355275,0.0001055023,0.0001077534],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.280574,0.009696161,0.1307592,0.00008067227,0.003476125,0.0008996917,0.008018509,0.0001034069,0.0003008669,0.003579602,0.534076,0.0284357],"study_design_scores_gemma":[0.6403892,0.000864359,0.1368775,0.0009759368,0.0009103691,0.00001256857,0.003213436,0.0001588779,0.002278015,0.0007603972,0.2131226,0.0004368406],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9524387,0.007531484,0.00001278893,0.02654571,0.001387637,0.004328724,0.0004334041,0.00007990389,0.007241606],"genre_scores_gemma":[0.9879158,0.001534102,0.00007651593,0.001109568,0.0002803102,0.001025217,0.0004066642,0.00002628198,0.007625566],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3598152,"threshold_uncertainty_score":0.9988485,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417530849","doi":"10.1016/j.esmorc.2025.100092","title":"INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA, A PUSH PLATFORM STUDY","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"Anschutz Medical Campus, University of Colorado; Università degli Studi di Torino; Albert-Ludwigs-Universität Freiburg; Justus Liebig Universität Gießen; University of Texas MD Anderson Cancer Center; St. Jude Children's Research Hospital; Universitätsklinikum Hamburg-Eppendorf; School of Medicine, Duke University; Ohio State University; University of Pennsylvania; Children's Hospital of Philadelphia; Nationwide Children's Hospital; Massachusetts Institute of Technology","keywords":"Retrospective cohort study; Multicenter study; MEDLINE; Real world data","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.02273181365827817,"gpt":0.3061227501812337,"spread":0.2833909365229555,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001159473,0.0002002605,0.0004263838,0.0002179268,0.00009920781,0.00002839195,0.0001606206,0.00005189017,0.0002604288],"category_scores_gemma":[0.00004602668,0.0001701368,0.0001117296,0.0002836484,0.00004575371,0.0001057765,0.0001175,0.0001854102,0.00000958518],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001059916,"about_ca_system_score_gemma":0.000141929,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001855394,"about_ca_topic_score_gemma":0.0003460805,"domain_scores_codex":[0.9985799,0.00002883211,0.0003727687,0.0004099577,0.0003956822,0.000212834],"domain_scores_gemma":[0.9991487,0.00005033279,0.0001390159,0.00038424,0.0002078127,0.00006985147],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0004040528,0.006803215,0.9830014,0.00002868379,0.0006948314,0.0001083184,0.003536741,0.00001542952,0.0001637969,0.00002746482,0.0009523704,0.00426372],"study_design_scores_gemma":[0.01305444,0.001065343,0.9678473,0.0002780057,0.0003030268,0.000002191148,0.01282228,0.00008340429,0.003782432,0.00001936685,0.0006240078,0.0001181807],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9890491,0.0002569903,0.00001542262,0.0003137346,0.0006127048,0.001652321,0.00001668871,0.00004328545,0.00803972],"genre_scores_gemma":[0.9988617,0.0000304765,0.0001739583,0.0002243549,0.00009512754,0.000221654,0.00001285695,0.00001898385,0.0003609356],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01515405,"threshold_uncertainty_score":0.6937977,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417530842","doi":"10.1016/j.esmorc.2025.100077","title":"MANAGEMENT OF THE DUODENUM DURING RESECTION OF PRIMARY RETROPERITONEAL SARCOMA: SURGICAL AND ONCOLOGICAL OUTCOMES FROM A MULTICENTER STUDY","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Duodenum; Multicenter study; Resection; Surgical resection; Segmental resection","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.02062131295544494,"gpt":0.296546458373951,"spread":0.275925145418506,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007663522,0.000108953,0.0003745972,0.00004461307,0.00006060251,0.000005618213,0.00007585341,0.00005000126,0.00006282789],"category_scores_gemma":[0.00001411691,0.00006407437,0.00009828975,0.0001350708,0.00008741092,0.00002431432,0.0001751023,0.000111836,5.682303e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003771727,"about_ca_system_score_gemma":0.00004081524,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008846461,"about_ca_topic_score_gemma":0.00008748012,"domain_scores_codex":[0.9990935,0.00007747065,0.0002600579,0.000230985,0.0002214491,0.0001165534],"domain_scores_gemma":[0.9994805,0.00009418264,0.00007668319,0.0002742285,0.00004057068,0.00003385491],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0009398152,0.0009277188,0.9937838,0.0001470075,0.0005780742,0.0002424565,0.0002286477,0.000003391803,0.00009912661,0.00003146992,0.0001096192,0.0029089],"study_design_scores_gemma":[0.006997863,0.0002278869,0.9883958,0.0003822158,0.0002946507,0.000002571442,0.0009322793,0.000007053241,0.002393387,0.00001030831,0.0003095148,0.00004654693],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9952096,0.001372642,8.067033e-7,0.0009065879,0.0001918141,0.0007596692,0.00001374347,0.00001337525,0.001531712],"genre_scores_gemma":[0.9991133,0.0002118517,0.0001189432,0.00006931276,0.00002722921,0.00008841243,0.000004791319,0.00000624769,0.0003598878],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006058048,"threshold_uncertainty_score":0.2612877,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417530903","doi":"10.1016/j.esmorc.2025.100079","title":"PREOPERATIVE RADIOTHERAPY AND POSTOPERATIVE COMPLICATIONS AMONG PATIENTS WITH PRIMARY RETROPERITONEAL SARCOMA: A POST HOC ANALYSIS OF THE EORTC-62092 (STRASS) PHASE 3 RANDOMIZED CLINICAL TRIAL","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Randomized controlled trial; Post-hoc analysis; Clinical trial; Radiation therapy; Intention-to-treat analysis; Post hoc","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.01606725772035284,"gpt":0.3322600279144521,"spread":0.3161927701940993,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003275631,0.0002415047,0.001356887,0.0001771951,0.0001923093,0.00003214167,0.0001283656,0.0001016653,0.00006969149],"category_scores_gemma":[0.0001850501,0.0001324312,0.0004317163,0.0007562423,0.0008060824,0.00008830408,0.00004273597,0.0002283099,3.739856e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003863765,"about_ca_system_score_gemma":0.0005539578,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005049346,"about_ca_topic_score_gemma":0.0003299517,"domain_scores_codex":[0.9978618,0.0005440557,0.0006781554,0.0004536394,0.0002826679,0.0001796825],"domain_scores_gemma":[0.9979839,0.000707004,0.0002802248,0.0005009084,0.0004213318,0.0001066456],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.3406878,0.002037873,0.6373625,0.00001931694,0.0089135,0.000008338375,0.0007690298,0.00002049063,0.00001872078,0.0001888194,0.0005758151,0.009397763],"study_design_scores_gemma":[0.3948425,0.001120993,0.6002001,0.0001057363,0.002993637,7.907996e-7,0.0001005452,0.0002306696,0.0000891348,0.000003067289,0.0002222952,0.00009052698],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9908918,0.001670875,0.00009542761,0.002491308,0.0001535208,0.003585415,0.0002524391,0.00002147285,0.0008377814],"genre_scores_gemma":[0.9960921,0.0004301831,0.0005638212,0.001934741,0.00003903354,0.0005051268,0.000286495,0.00001622378,0.0001322719],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05415469,"threshold_uncertainty_score":0.5400389,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417530897","doi":"10.1016/j.esmorc.2025.100090","title":"CIRCULATING TUMOR DNA IN PATIENTS WITH INTERMEDIATE RISK RHABDOMYOSARCOMA ON ARST1431: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"School of Medicine, Duke University; Università degli Studi di Padova; Centre Léon Bérard; Ohio State University; Institut Gustave-Roussy; Nationwide Children's Hospital","keywords":"Circulating tumor DNA; Rhabdomyosarcoma; Mutation; Retrospective cohort study; Disease; Circulating tumor cell; Cancer","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.003196162349068001,"gpt":0.2168799504972371,"spread":0.2136837881481691,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001402174,0.0001945635,0.000220387,0.00004659935,0.000102798,0.00002867725,0.0002604339,0.0001082272,0.00001550947],"category_scores_gemma":[0.0002871805,0.000150102,0.00007166292,0.0001436509,0.0001131465,0.000003594309,0.0001462607,0.0002444907,0.00000280832],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002812495,"about_ca_system_score_gemma":0.0004095852,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002392098,"about_ca_topic_score_gemma":0.004190274,"domain_scores_codex":[0.9987386,0.00007688904,0.0002924792,0.0005030362,0.0001208369,0.0002681854],"domain_scores_gemma":[0.9990071,0.0001160562,0.0002267114,0.0005379404,0.00005926583,0.00005289919],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.000584444,0.0001067878,0.9750984,0.000005357081,0.0001598149,0.00009563455,0.0001168986,0.0004369615,0.0002700416,0.00004142204,0.006480457,0.0166038],"study_design_scores_gemma":[0.002427407,0.0004685295,0.9777695,0.00009856411,0.0000467113,0.000006368318,0.00006987214,0.00003679693,0.00119927,0.0001482441,0.01751612,0.0002126248],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9970235,0.0003892153,0.0001795102,0.0002912668,0.0004849479,0.0004067122,0.0002170467,0.00001047583,0.0009972764],"genre_scores_gemma":[0.9960476,0.00010962,0.0001287266,0.00273509,0.0002628231,0.00007832877,0.0005854002,0.00002290372,0.00002952913],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01639117,"threshold_uncertainty_score":0.6120981,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417530898","doi":"10.1016/j.esmorc.2025.100059","title":"DISSECTING TUMOR HETEROGENEITY AND CELL STATE-SPECIFIC THERAPEUTIC TARGETS FROM SINGLE-NUCLEI RNA-SEQ OF CIC::DUX4 ROUND CELL SARCOMA","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Sarcoma; Cell; Tumor cells; Clear-cell sarcoma; Chemotherapy; Cell culture","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.02383050455828387,"gpt":0.2642154732002451,"spread":0.2403849686419612,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008601198,0.0002983768,0.0005488538,0.0001138387,0.000133467,0.00004690768,0.0001201339,0.00007656359,0.0001732021],"category_scores_gemma":[0.00001533394,0.0002584842,0.0001523806,0.0002245083,0.0001012161,0.00008352457,0.00007586076,0.0001913061,0.000008739443],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005928317,"about_ca_system_score_gemma":0.0001344117,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001217053,"about_ca_topic_score_gemma":0.0003730125,"domain_scores_codex":[0.9984276,0.00005623236,0.0003926921,0.0005306572,0.0002356366,0.0003571416],"domain_scores_gemma":[0.9988515,0.0002516735,0.0001827593,0.0004461592,0.0001215646,0.0001462877],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001093804,0.002218672,0.8167098,0.00061881,0.0008295589,0.0006600385,0.002244484,0.0000749152,0.09460497,0.00007086426,0.003046274,0.07782784],"study_design_scores_gemma":[0.004510332,0.0003937372,0.2541945,0.0003465163,0.0003085562,0.000008300271,0.001074997,0.000133375,0.7270891,0.0004966314,0.01111904,0.0003249253],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9511927,0.04479362,0.00008365804,0.0003575046,0.0004638331,0.0004451719,0.0001249182,0.00005782735,0.002480734],"genre_scores_gemma":[0.9974234,0.0008402677,0.0005703853,0.0005997478,0.0001002226,0.00004852853,0.00005705158,0.0000416977,0.0003187321],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6324841,"threshold_uncertainty_score":0.9999867,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417530862","doi":"10.1016/j.esmorc.2025.100084","title":"PREDICTING FAILURE OF ACTIVE SURVEILLANCE IN DESMOID-TYPE FIBROMATOSIS USING RADIOMICS: AN INTERNATIONAL MULTI-CENTER STUDY","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Soft tissue tumor case studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; Sinai Health System","funders":"Sylvester Comprehensive Cancer Center, University of Miami Health Systems; Thomas Jefferson University; University of Miami","keywords":"Radiomics; Fibromatosis; Medical imaging; MEDLINE; Personalized medicine","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.03232056340378441,"gpt":0.3448138099901654,"spread":0.312493246586381,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001669187,0.0001747674,0.0004390457,0.0002681795,0.00005885132,0.00001133366,0.0001504165,0.00006025391,0.00004596308],"category_scores_gemma":[0.0003641564,0.0001762295,0.00005619568,0.0004661586,0.00008764889,0.0001751631,0.000101744,0.0002041057,0.000001300396],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000785726,"about_ca_system_score_gemma":0.0002628092,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002096516,"about_ca_topic_score_gemma":0.002240652,"domain_scores_codex":[0.9987769,0.00008363263,0.0003524064,0.0003613315,0.0002144928,0.0002113074],"domain_scores_gemma":[0.9991884,0.00009940747,0.0001369329,0.0002870384,0.0002370951,0.00005108024],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0004975817,0.0003387141,0.9927775,0.00008066436,0.0003702125,0.0000768406,0.003583429,0.0002074164,0.00113741,0.000005270239,0.0001194172,0.0008055265],"study_design_scores_gemma":[0.007046506,0.0002667727,0.9720288,0.0006475388,0.0000680449,0.00002603108,0.01177691,0.004191141,0.003492479,0.000004783223,0.0002894441,0.0001615733],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9980602,0.0001958164,0.00006283064,0.000184154,0.0005626345,0.0005878378,0.00004252385,0.00005702698,0.0002469785],"genre_scores_gemma":[0.9982066,0.00003187872,0.001404238,0.00009592791,0.000101804,0.00002494057,0.0000275701,0.00002156117,0.00008553389],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02074874,"threshold_uncertainty_score":0.7186431,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417530895","doi":"10.1016/j.esmorc.2025.100055","title":"IMMUNOSARC2 (COHORT 7A): A SPANISH SARCOMA GROUP (GEIS) PHASE IB TRIAL OF EPIRUBICIN AND IFOSFAMIDE PLUS NIVOLUMAB IN FIRST LINE OF ADVANCED UNDIFFERENTIATED PLEOMORPHIC SARCOMA (UPS)","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Duke Cancer Institute; National Cancer Institute; Knight Cancer Institute, Oregon Health and Science University; University of Texas MD Anderson Cancer Center; University of California, Irvine; USC Norris Comprehensive Cancer Center; McGill University Health Centre; Huntsman Cancer Institute; McGill University; Royal Marsden NHS Foundation Trust; Medical Center, University of Pittsburgh; University of Pittsburgh; Washington University in St. Louis; Moffitt Cancer Center; Centre Hospitalier Universitaire de Bordeaux; University of Southern California; National Institutes of Health; Ohio State University; Memorial Sloan-Kettering Cancer Center; Children's Hospital of Philadelphia","keywords":"Nivolumab; Ifosfamide; Epirubicin; Sarcoma; First line; Chemotherapy","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.02086258826529606,"gpt":0.3186337084991464,"spread":0.2977711202338503,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003038421,0.0003692691,0.001256459,0.0005436125,0.00009838916,0.00001629491,0.0002336632,0.0001940184,0.0002878234],"category_scores_gemma":[0.0004988987,0.0003409772,0.0001951836,0.0008102265,0.0003451445,0.0001381496,0.0001647334,0.0004237319,0.000003887915],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00081694,"about_ca_system_score_gemma":0.0007132813,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.009569853,"about_ca_topic_score_gemma":0.00587643,"domain_scores_codex":[0.9972021,0.0001655131,0.0009092599,0.0006014639,0.0005316135,0.0005900539],"domain_scores_gemma":[0.9982678,0.0003747737,0.0002817373,0.0006653774,0.0001891211,0.0002212478],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.3631703,0.005538309,0.4936384,0.002692387,0.00309893,0.001314368,0.0009471375,0.000151321,0.0249856,0.0004314617,0.0007882977,0.1032435],"study_design_scores_gemma":[0.4650464,0.005032033,0.5030646,0.002155463,0.0004386372,0.00002500871,0.0002937957,0.003350575,0.01866685,0.0002673973,0.001267507,0.0003916897],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9923073,0.003454718,0.0001618804,0.000419182,0.0002789595,0.002619923,0.0002563859,0.00004850329,0.0004531184],"genre_scores_gemma":[0.9962707,0.002144868,0.0002428938,0.00007572161,0.00006874132,0.0002301025,0.0004654557,0.0000411568,0.0004603279],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1028518,"threshold_uncertainty_score":0.9999042,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417530860","doi":"10.1016/j.esmorc.2025.100076","title":"GENOME-WIDE SEQUENCING ANALYSES REVEAL THE BIOLOGICAL DETERMINANTS OF RESECTION MARGIN STATUS IN PRIMARY RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; Hospital for Sick Children; Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"","keywords":"Liposarcoma; Resection margin; Resection; Margin (machine learning); Surgical margin; Radiation therapy","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.05800347749770376,"gpt":0.3336131826764603,"spread":0.2756097051787566,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001672934,0.0001726435,0.0004784112,0.0002050377,0.00008384571,0.00001354891,0.0001118603,0.0001166014,0.00007347549],"category_scores_gemma":[0.000158363,0.0001065034,0.0001236328,0.0005615497,0.000129219,0.00004565174,0.00007598763,0.0002243148,0.000002436941],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001622576,"about_ca_system_score_gemma":0.0004746189,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002879597,"about_ca_topic_score_gemma":0.0009773425,"domain_scores_codex":[0.9985831,0.0001597655,0.0004184879,0.0003185874,0.0001875211,0.0003325839],"domain_scores_gemma":[0.9991977,0.0002032101,0.0001210019,0.0003263389,0.00008567882,0.00006604972],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0005291565,0.0001056086,0.9840344,0.00009470733,0.0001321748,0.0001860446,0.0001638632,0.00001805479,0.008656792,0.000004458761,0.0002117801,0.005863003],"study_design_scores_gemma":[0.001403356,0.0002430204,0.971127,0.0003621972,0.000113493,0.00001310843,0.0003037725,0.00005591842,0.02596951,0.00003936673,0.0002816413,0.00008765436],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.992957,0.005145058,0.000008132997,0.0003536234,0.0001821175,0.0004442128,0.00002491792,0.00002780406,0.0008571084],"genre_scores_gemma":[0.9979092,0.001157983,0.0001668201,0.0003932802,0.00005644513,0.0000979747,0.00007293028,0.00001134227,0.0001340641],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01731272,"threshold_uncertainty_score":0.4353108,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417530877","doi":"10.1016/j.esmorc.2025.100056","title":"INTEGRATED EFFICACY AND SAFETY ANALYSIS OF LETETRESGENE AUTOLEUCEL, A T-CELL RECEPTOR T-CELL THERAPY, ACROSS CLINICAL TRIALS OF PATIENTS WITH SYNOVIAL SARCOMA AND MYXOID/ROUND CELL LIPOSARCOMA","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre","funders":"","keywords":"Clinical trial; Soft tissue sarcoma; Synovial sarcoma; Liposarcoma; Sarcoma; Receptor","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.03792771047108455,"gpt":0.355637362170223,"spread":0.3177096516991384,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001013006,0.0004007695,0.002169674,0.0003293107,0.0001131811,0.00003389695,0.0001534608,0.0002384828,0.0002028463],"category_scores_gemma":[0.0002036903,0.0002777149,0.0004040408,0.001133689,0.0004176621,0.00006947687,0.00009507673,0.000277709,0.000001458541],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002178897,"about_ca_system_score_gemma":0.000479322,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009679789,"about_ca_topic_score_gemma":0.0001899654,"domain_scores_codex":[0.9965246,0.0005249637,0.00152122,0.000692911,0.0003784433,0.0003578518],"domain_scores_gemma":[0.9964064,0.001681802,0.0007564691,0.000581242,0.0003548625,0.0002191617],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0103955,0.004406597,0.8962274,0.0002168702,0.003920887,0.00002229925,0.0006630708,0.00002136721,0.001875503,0.000008492405,0.001122412,0.0811196],"study_design_scores_gemma":[0.04208862,0.003318063,0.9133204,0.0003236215,0.004158206,8.983029e-7,0.0005739065,0.0001521449,0.02794521,0.000005331874,0.007785629,0.0003279238],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9859402,0.01107125,0.00005062832,0.0002160743,0.0002069541,0.001181629,0.0009098681,0.00003174142,0.0003916215],"genre_scores_gemma":[0.9945206,0.003675027,0.0007604071,0.0002449859,0.00004801015,0.00005235911,0.0004333386,0.00003279738,0.0002324791],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08079167,"threshold_uncertainty_score":0.9999675,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W7116631298","doi":"10.1016/j.esmorc.2025.100103","title":"PRELIMINARY DOSE-VOLUME CONSTRAINTS PREDICTING SUBCUTANEOUS TISSUE FIBROSIS FOR LIMB SARCOMA USING THE VORTEX AND IMRIS TRIALS","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Fibrosis; Soft tissue sarcoma; Soft tissue; Thigh; Sarcoma; Subcutaneous tissue; Vortex","authors":[{"name":"Rita Simões","is_ca":false},{"name":"Beatrice Seddon","is_ca":false},{"name":"M. Robinson","is_ca":false},{"name":"Shumona Shelly","is_ca":false},{"name":"Temi Adedoyin","is_ca":false},{"name":"Hakim-Moulay Dehbi","is_ca":false},{"name":"Piers Gaunt","is_ca":false},{"name":"Ana Hughes","is_ca":false},{"name":"Elizabeth Miles","is_ca":false},{"name":"Peter Hoskin","is_ca":false},{"name":"K. Harrington","is_ca":true},{"name":"S. Gulliford","is_ca":false},{"name":"Dr Aisha Miah","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04187978627994771,"gpt":0.3401438212695845,"spread":0.2982640349896368,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004267318,0.0002463122,0.0006584196,0.0000973742,0.0002967055,0.00006223434,0.0001026666,0.0001386821,0.0001583964],"category_scores_gemma":[0.0005208803,0.0001740835,0.000187303,0.00018431,0.0002371856,0.00005782284,0.00006683341,0.0001478752,0.000002665312],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003688819,"about_ca_system_score_gemma":0.0003758674,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004989105,"about_ca_topic_score_gemma":0.00003748196,"domain_scores_codex":[0.9984396,0.000115994,0.0004927256,0.0004202129,0.000179341,0.0003521708],"domain_scores_gemma":[0.9979792,0.001262562,0.0001904985,0.0003475403,0.0001084253,0.0001117389],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.005843031,0.0004760225,0.3363367,0.0009551413,0.002458397,0.0007973631,0.002091026,0.0001483821,0.00489978,0.0004826219,0.02277215,0.6227394],"study_design_scores_gemma":[0.04307815,0.01224958,0.6525518,0.00889443,0.01675509,0.00446667,0.01141097,0.01955902,0.0799652,0.002723991,0.1461905,0.002154635],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9716659,0.01898696,0.0004957396,0.004335823,0.000671868,0.002709419,0.0002610232,0.00009932789,0.0007739102],"genre_scores_gemma":[0.9955705,0.0004511529,0.002007836,0.0007294267,0.0002916495,0.0003092764,0.0000404456,0.0000303756,0.0005692687],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6205847,"threshold_uncertainty_score":0.7098921,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417530841","doi":"10.1016/j.esmorc.2025.100102","title":"NRG-DT001 PHASE IB TRIAL OF NEOADJUVANT NAVTEMADLIN AND RADIOTHERAPY IN TP53 WILD-TYPE SOFT TISSUE SARCOMA: PRELIMINARY EFFICACY ANALYSIS","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Soft tissue sarcoma; Radiation therapy; Tolerability; Soft tissue; Sarcoma; Clinical trial; Phases of clinical research","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.01758124853013332,"gpt":0.3460718606338129,"spread":0.3284906121036796,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002098338,0.0002600464,0.001006491,0.0005351044,0.00005535974,0.00001601596,0.0001139147,0.0001468573,0.0002141031],"category_scores_gemma":[0.00009982463,0.0002211032,0.0001997099,0.001271308,0.0001201225,0.00007463141,0.00003883564,0.0001800461,0.000002379352],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004042135,"about_ca_system_score_gemma":0.0003566481,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001334139,"about_ca_topic_score_gemma":0.0002008284,"domain_scores_codex":[0.9983391,0.0001016221,0.0005389358,0.0004807198,0.0002505421,0.0002890602],"domain_scores_gemma":[0.9988047,0.0003357834,0.0001526467,0.0004945326,0.00008693003,0.0001253693],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1240937,0.007851469,0.1545779,0.0004058016,0.006368833,0.001420904,0.002249327,0.0008797604,0.00106506,0.0002829843,0.008774274,0.6920299],"study_design_scores_gemma":[0.5569036,0.01190938,0.3617879,0.001677466,0.008183632,0.00005245706,0.0006726491,0.004397047,0.01438113,0.0002962632,0.03890818,0.0008302332],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.956458,0.03947091,0.0001257168,0.001909669,0.0003278638,0.001227903,0.00002936712,0.00004077969,0.0004097882],"genre_scores_gemma":[0.9950492,0.003170456,0.0006113251,0.0004543223,0.0001400716,0.0001116971,0.0000893758,0.00002299433,0.0003505726],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6911997,"threshold_uncertainty_score":0.9016325,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417530851","doi":"10.1016/j.esmorc.2025.100096","title":"DATA DRIVEN MODELLING OF SPATIAL HETEROGENEITY IN SOFT TISSUE SARCOMAS IDENTIFIES PROGNOSTIC GROUPS FOLLOWING NEOADJUVANT CHEMOTHERAPY: ANALYSIS OF THE ISG-STS-1001 TRIAL","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Soft tissue; Radiation therapy; Neoadjuvant therapy; Data-driven; Tumour heterogeneity; Sarcoma; Spatial heterogeneity","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.02480526418381184,"gpt":0.2916081398782909,"spread":0.2668028756944791,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002280167,0.0001613283,0.0004151375,0.0001030542,0.00006380319,0.00002241477,0.0006679444,0.0001324882,0.00001890126],"category_scores_gemma":[0.0001402151,0.0001491763,0.0002322282,0.0003794076,0.000101235,0.00000762859,0.0003810816,0.00009773578,2.954447e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006630907,"about_ca_system_score_gemma":0.0003796229,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003475429,"about_ca_topic_score_gemma":0.01800421,"domain_scores_codex":[0.9986768,0.00006090113,0.0004267777,0.0004550334,0.0001706681,0.0002098448],"domain_scores_gemma":[0.9986752,0.00006501525,0.0002084913,0.0009509607,0.00006712234,0.00003317508],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"simulation_or_modeling","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.006783893,0.0005491268,0.2607071,0.0003237032,0.006779862,0.00002247367,0.001156045,0.587612,0.1047606,0.0001228204,0.002564834,0.02861748],"study_design_scores_gemma":[0.04616774,0.0009324342,0.08898965,0.0008002587,0.005756571,0.000002838801,0.0007528338,0.3507789,0.4858865,0.0009249498,0.01747046,0.001536864],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9749292,0.003139068,0.02025262,0.0001423899,0.0006100601,0.000486091,0.0003622301,0.000004881331,0.0000735244],"genre_scores_gemma":[0.9985169,0.0005233011,0.0002659473,0.0001293903,0.0001179818,0.00002142557,0.0003633134,0.00001575169,0.00004602147],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3811258,"threshold_uncertainty_score":0.9999146,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417530885","doi":"10.1016/j.esmorc.2025.100072","title":"OVERCOMING MTOR INHIBITOR RESISTANCE IN PECOMA: UPDATED RESULTS ON AROMATASE INHIBITOR ADDITION FROM A REFERRAL CENTER","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Nitric Oxide and Endothelin Effects","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research","funders":"Memorial Sloan-Kettering Cancer Center","keywords":"Discovery and development of mTOR inhibitors; Aromatase inhibitor; Aromatase; Clinical trial; PI3K/AKT/mTOR pathway; Referral","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.01383670230329569,"gpt":0.2705782362036146,"spread":0.2567415339003189,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001835097,0.0002670329,0.0004431511,0.0003056354,0.00008303682,0.00003012793,0.000117846,0.000195973,0.0002280789],"category_scores_gemma":[0.0003542239,0.0002513417,0.0001051225,0.0005148823,0.00005371582,0.0001592852,0.00005044073,0.0004740311,0.0000903307],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001176216,"about_ca_system_score_gemma":0.000274718,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007223439,"about_ca_topic_score_gemma":0.001484233,"domain_scores_codex":[0.9981089,0.0001107505,0.0005072572,0.0005928442,0.0002886895,0.0003916003],"domain_scores_gemma":[0.9989043,0.0002320144,0.0001337181,0.0005345921,0.00006440882,0.000130894],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01660744,0.0003589195,0.005642962,0.000208255,0.0001129624,0.0008947413,0.0005465399,0.00001361569,0.005922129,0.0002084197,0.9665321,0.002951968],"study_design_scores_gemma":[0.05106739,0.0006754847,0.1264976,0.01202697,0.0002166399,0.00001302977,0.0006721549,0.0002730504,0.08327213,0.001117497,0.7231701,0.0009979864],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9729269,0.0005293359,0.00001403043,0.003092311,0.001441185,0.0006687475,0.002042019,0.0001655029,0.01911997],"genre_scores_gemma":[0.9909638,0.00007505099,0.0004956438,0.002662917,0.0008235622,0.00009161163,0.002323473,0.00003342738,0.002530483],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.243362,"threshold_uncertainty_score":0.9999939,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417530910","doi":"10.1016/j.esmorc.2025.100062","title":"MINNELIDE IS A NOVEL THERAPEUTIC INHIBITOR OF CIC::DUX4 SARCOMA","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Magnesium in Health and Disease","field":"Nursing","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Sarcoma; Cancer; Immunotherapy; Soft tissue sarcoma; Drug","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.01910175830934603,"gpt":0.3049709616630899,"spread":0.2858692033537439,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001088442,0.0001773087,0.0002681406,0.000151575,0.0001183134,0.00002016499,0.0002156668,0.0001141018,0.0007608674],"category_scores_gemma":[0.0000880916,0.0001738109,0.0001189411,0.000427233,0.0001040154,0.00008682597,0.00003895611,0.0001564655,0.00002101538],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002685687,"about_ca_system_score_gemma":0.0004570515,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001348244,"about_ca_topic_score_gemma":0.000114497,"domain_scores_codex":[0.9986771,0.00004324324,0.0003636807,0.000322175,0.0002134361,0.0003803723],"domain_scores_gemma":[0.9990337,0.0001252573,0.0001204006,0.0004302822,0.000126693,0.0001636112],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.009123942,0.001096464,0.1402747,0.01256928,0.0001995328,0.00004403628,0.007276993,0.0001231411,0.02451724,0.006813947,0.4074579,0.3905028],"study_design_scores_gemma":[0.01169356,0.0009435553,0.1563114,0.001022499,0.0006648031,0.00001213028,0.00206059,0.002691833,0.2125865,0.007825093,0.6028058,0.001382271],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8695884,0.02598305,0.00083934,0.04196671,0.01109219,0.001851376,0.0005533783,0.0003748044,0.04775078],"genre_scores_gemma":[0.9826685,0.00001299454,0.0002599631,0.01567578,0.0002576568,0.0000567407,0.00001213976,0.00002038501,0.001035913],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3891205,"threshold_uncertainty_score":0.8330964,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W7116631937","doi":"10.1016/j.esmorc.2025.100070","title":"EXPLORING ACTIONABLE THERAPEUTIC TARGETS ASSOCIATED WITH SMARCB1 DEFICIENCY IN EPITHELIOID SARCOMA","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Epithelioid sarcoma; Sarcoma; SMARCB1; Disease; Mutation; Soft tissue sarcoma","authors":[{"name":"Ryo Miyamoto","is_ca":true},{"name":"J. Park","is_ca":true},{"name":"David G. Kirsch","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03014984236719089,"gpt":0.2573838991908916,"spread":0.2272340568237007,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001252297,0.0001396993,0.0001397257,0.00007233509,0.00009434142,0.00001842697,0.0001441113,0.00008019374,0.00003489962],"category_scores_gemma":[0.0000364271,0.0001264879,0.00004731418,0.0002858216,0.0000482378,0.000009284859,0.00003776481,0.0001233176,0.00000257189],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002427245,"about_ca_system_score_gemma":0.0003733738,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000249749,"about_ca_topic_score_gemma":0.0008766648,"domain_scores_codex":[0.9990999,0.00004136694,0.0001525639,0.0003169191,0.0001135825,0.0002756288],"domain_scores_gemma":[0.9996009,0.00001618174,0.0000536296,0.0002288101,0.00006761602,0.00003284589],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.002270061,0.0009325102,0.169047,0.0005838198,0.00127643,0.0001028571,0.002767765,0.1027318,0.4791807,0.001987486,0.01560081,0.2235187],"study_design_scores_gemma":[0.01020756,0.001198382,0.19941,0.001578722,0.0001883698,0.00002648427,0.003345033,0.006479945,0.6427519,0.001719255,0.130879,0.002215347],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9870236,0.005558317,0.001336296,0.0002610041,0.0002799279,0.0001588988,0.00001243914,0.00003259756,0.005336915],"genre_scores_gemma":[0.9974676,0.0005759239,0.0001172385,0.0004380078,0.00005554461,0.0001127402,0.0000520081,0.00001770305,0.001163196],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2213034,"threshold_uncertainty_score":0.5158027,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417530843","doi":"10.1016/j.esmorc.2025.100061","title":"JAK/STAT PATHWAY CO-OPERATES WITH CIC-FUSIONS TO DRIVE CIC-REARRANGED SARCOMAS","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Mount Sinai Hospital; University Health Network; Barrie Urology Group","funders":"","keywords":"Sarcoma; Mutation; Cancer; Cell culture","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.01703091906346409,"gpt":0.3220248881436876,"spread":0.3049939690802235,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00009972935,0.0002701796,0.0004190486,0.0002580319,0.0002803946,0.00005119712,0.0001676752,0.00009356836,0.001162034],"category_scores_gemma":[0.000148192,0.0001944192,0.00008989074,0.0005629986,0.0001192704,0.00008562741,0.00007386673,0.0002928411,0.0002531774],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006551251,"about_ca_system_score_gemma":0.001186359,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001596661,"about_ca_topic_score_gemma":0.001790632,"domain_scores_codex":[0.9982013,0.0000693301,0.0002097589,0.0005014595,0.0004260869,0.000592052],"domain_scores_gemma":[0.9985753,0.0001233512,0.00003796303,0.0005386464,0.0002291591,0.000495624],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.007611084,0.0007983856,0.6251092,0.0005130927,0.002467038,0.004554381,0.004907195,0.0001619958,0.02593615,0.001035782,0.1873001,0.1396056],"study_design_scores_gemma":[0.01892586,0.002567171,0.4486099,0.001769794,0.0002746952,0.0000837085,0.002785155,0.0003420808,0.1090499,0.0001045755,0.4147131,0.0007740361],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9232122,0.001486318,0.0003112583,0.01020976,0.0003156233,0.002270631,0.0003343883,0.000225189,0.06163465],"genre_scores_gemma":[0.9810452,0.0001542504,0.001119938,0.002096704,0.0001360265,0.0003449961,0.0002222647,0.00003712562,0.01484352],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.227413,"threshold_uncertainty_score":0.999751,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}